

(Print or Type Responses)

1. Name and Address of Reporting Person* Dunne Michael W.			2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)				
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, FITZWILLIAM COURT, FL. 1, LEESON CLOSE			3. Date of Earliest Transaction (Month/Day/Year) 03/25/2022								
(Street) DUBLIN 2, L2			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares		03/25/2022		M		10,494 A		\$ 0 (1)		346,849	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
								Date Exercisable	Expiration Date						
				Code	V	(A)	(D)			Title	Amount or Number of Shares				
Restricted Share Units	(1)	03/25/2022		M			10,494	(2)	(2)	Ordinary Shares	10,494	\$ 0	0	D	
Restricted Share Units	(3)	03/25/2022		A		11,426		(4)	(4)	Ordinary Shares	11,426	\$ 0	11,426	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Dunne Michael W. C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE DUBLIN 2, L2	X			

Signatures

/s/ Michael W. Dunne	03/29/2022
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Restricted share units ("2021 RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the 2021 RSUs.

(2) On March 25, 2021, the reporting person was granted an award of 10,494 2021 RSUs, which vested on March 25, 2022.

(3) Each restricted share unit ("2022 RSU") represents the contingent right to receive one ordinary share upon vesting of a 2022 RSU.

(4) Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the 2022 RSUs shall vest in full on January 1, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.